Design and Synthesis of Tetrahydropyrrolo[3,4-c]Pyrazole Sigma-1 Receptor Ligands

Area of Science:

• Medicinal Chemistry
• Neuropharmacology
• Drug Discovery

Background:

• Sigma-1 receptor (S1R) ligands are investigated for therapeutic potential.
• Developing selective S1R ligands with reduced off-target effects, particularly hERG channel inhibition, remains a challenge.

Purpose of the Study:

• To design and synthesize novel tetrahydropyrrolo[3,4-c]pyrazole derivatives as S1R ligands.
• To optimize ligand affinity for S1R while minimizing binding to S2R and reducing cardiotoxicity.

Main Methods:

• Synthesis of tetrahydropyrrolo[3,4-c]pyrazole derivatives.
• Radioligand binding assays to determine affinity for S1R and S2R.
• In vitro assessment of hERG channel inhibition for cardiotoxicity evaluation.

Main Results:

• Compound 19 (AD417) exhibited significant S1R affinity (K_i=75 nM) and 6-fold selectivity over S2R.
• Modifications on the pyrrolidine nitrogen were key for receptor interaction, potentially involving a protonated nitrogen interacting with Glu172.
• Compound 19 demonstrated a safer cardiotoxicity profile with a hERG IC₅₀ of 5.8 μM, compared to verapamil and haloperidol.

Conclusions:

• Tetrahydropyrrolo[3,4-c]pyrazole scaffolds can be optimized for selective S1R binding.
• Structural modifications, particularly on the pyrrolidine nitrogen, are critical for enhancing S1R affinity and selectivity.
• Compound 19 represents a promising lead for developing S1R-targeted therapeutics with a reduced risk of hERG-related cardiotoxicity.